middle.news
How Will Percheron’s HMBD-002 Phase II Trial Shape Its Future?
1:02pm on Thursday 26th of February, 2026 AEDT
•
Biotechnology
Read Story
How Will Percheron’s HMBD-002 Phase II Trial Shape Its Future?
1:02pm on Thursday 26th of February, 2026 AEDT
Key Points
64% reduction in net loss to $3.1 million for H1 FY26
Exclusive worldwide license secured for HMBD-002 from Hummingbird Bioscience
Phase II clinical trial for HMBD-002 planned to start in second half of 2026
Discontinuation of Avicursen development following negative phase II data
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE